Gregory M. LAIRD,Robert SILICIANO,Cynthia K. BULLEN
申请号:
US15552452
公开号:
US20180169108A1
申请日:
2016.02.19
申请国别(地区):
US
年份:
2018
代理人:
摘要:
Provided herein are effective latency-reversing agent (LRA) combinations of drugs for the reversal of HIV-1 latency. Such methods utilize, for example, the combination of a protein kinase C agonist and a bromodomain inhibitor combine to reverse latency or a NFκB activator combined with histone deacetylase inhibitors to reverse latency. These findings are surprising considering that many of the individual drug in these combinations show no effect alone. Novel drug combinations for reversal of HIV-1 latency/reactivation of latent HIV-1 may include 1) disulfiram (acetaldehyde dehydrogenase inhibitor, activator of NF-κB via AKT signaling) plus histone deacetylase inhibitors or 2) protein kinase C agonists with bromodomain inhibitor JQ1. Latency-reversing drug combinations for use in HIV-1 infected individuals may eliminate the HIV-1 reservoir for cure/long-term drug-free remission.